Atomoxetine (CAS 83015-26-3) ADHD-Treating API

Atomoxetine (CAS 83015-26-3) is a premium ADHD-treating API with a unique mechanism as a selective norepinephrine reuptake inhibitor. It presents as a white to off-white crystalline powder, manufactured under strict GMP standards to ensure ≥99% purity and excellent molecular stability, guaranteeing consistent bioactivity in pharmaceutical formulations. By selectively inhibiting norepinephrine reuptake, it enhances neurotransmitter levels in the brain, effectively improving attention span, reducing impulsivity, and controlling hyperactivity.

This pharmaceutical-grade API complies with global pharmacopoeia requirements (USP/EP/BP), making it ideal for pharmaceutical manufacturers, biotech firms, and neuropharmacology research institutions. It offers reliable batch-to-batch consistency, strong formulation compatibility, and clinically validated efficacy. For those seeking a high-quality, targeted raw material to develop ADHD therapeutics, Atomoxetine stands out as a trusted and cost-effective solution to support the creation of safe and effective treatments.